Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Novel MUC1 Theranostic Peptides for Imaging and Treatment of Triple-Negative Breast Cancer

Award Number: R37CA278744
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 03/01/2024
PERIOD OF PERFORMANCE END DATE: 02/28/2029

Group Awards By:

View Award Description

Novel MUC1 Theranostic Peptides for Imaging and Treatment of Triple-Negative Breast Cancer - Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer defined by a poor overall prognosis, aggressive and early pattern of metastases, and a lack of treatments that lead to sustained disease control. There is a critical need for molecular targeted treatments for patients with TNBC that are more effective, have reduced side effects, and decrease the mortality associated with TNBC. Mucin-1 (MUC1) is overexpressed and underglycosylated in 94% of TNBC and the receptor density is extremely high. The combination of the modification of the glycosylation and overexpression allow tumor associated MUC1 distinguishable and targetable from normal tissue. Targeted radionuclide therapy (TRT) is a molecular targeted treatment that specifically uses radiolabeled moieties as biological targeting vectors intended to deliver localized cytotoxic radiation to cancer cells that overexpress specific receptors, without harming normal cells. We propose to combine the suitability of MUC1 as a therapeutic target in TNBC with the promising technique of TRT to develop a novel theranostic peptide for diagnostic imaging and TRT of TNBC. The aims of this proposal are to develop MUC1 targeted peptides that can successfully be applied for TRT, exhibiting properties suitable for clinical translation. The advantages of peptides over previously studied antibody radioisotope complexes include the superior pharmacokinetics, low immunogenicity, and ease of synthesis for widespread application. In Aim 1 we will determine the mechanism and specificity of peptide binding, optimize the incorporation of a metal chelator through various spacer moieties, and employ different cyclization strategies to improve peptide affinity and stability. In Aim 2 we will radiolabel three peptide sequences with promising binding affinities with gallium-68 and lutetium-177. We will complete a comprehensive analysis of binding and internalization in TNBC cells, and determine in vivo tumor targeting properties and biodsitribution in mouse models of TNBC. In Aim 3, we will advance the most promising peptide sequence, identified through quantitative metrics, to therapeutic studies and determine the ability of MUC1 TRT to treat TNBC in mouse models. We will additionally complete a preliminary safety assessment. Through these studies we will also understand any issues related to proceeding with clinical translation of the MUC1 theranostic peptide for application in TNBC. Given the mortality associated with TNBC and the critical need for targeted treatments, this MUC1 TRT will have high impact for the treatment and management of TNBC. We will provide proof of concept that MUC1 is a valid therapeutic target and that TRT can effectively treat TNBC. We intend for our results to lay the foundation for subsequent development of randomized, controlled clinical trials that test this promising treatment in patients with TNBC. If successful, this will be a significant step forward for reducing the mortality associated with TNBC.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $485,341 )
2026	2026	THE LELAND STANFORD JUNIOR UNIVERSITY	450 JANE STANFORD WAY	STANFORD	CA	94305	SANTA CLARA	USA	Cancer Treatment Research	000	3	2/26/2026	NON-COMPETING CONTINUATION	$485,341
														Subtotal = $485,341

Issue Date FY: 2025 ( Subtotal = $475,676 )
2025	2025	THE LELAND STANFORD JUNIOR UNIVERSITY	450 JANE STANFORD WAY	STANFORD	CA	94305	SANTA CLARA	USA	Cancer Treatment Research	000	2	2/13/2025	NON-COMPETING CONTINUATION	$428,108
2025	2025	THE LELAND STANFORD JUNIOR UNIVERSITY	450 JANE STANFORD WAY	STANFORD	CA	94305	SANTA CLARA	USA	Cancer Treatment Research	001	2	5/22/2025	NON-COMPETING CONTINUATION	$47,568
														Subtotal = $475,676

Issue Date FY: 2024 ( Subtotal = $462,860 )
2024	2024	THE LELAND STANFORD JUNIOR UNIVERSITY	450 JANE STANFORD WAY	STANFORD	CA	94305	SANTA CLARA	USA	Cancer Treatment Research	001	1	6/28/2024	NEW	$0
2024	2024	THE LELAND STANFORD JUNIOR UNIVERSITY	450 JANE STANFORD WAY	STANFORD	CA	94305	SANTA CLARA	USA	Cancer Treatment Research	000	1	1/10/2024	NEW	$462,860
														Subtotal = $462,860

Grand Total All Awards = $1,423,877

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Novel MUC1 Theranostic Peptides for Imaging and Treatment of Triple-Negative Breast Cancer

Award Number: R37CA278744

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 03/01/2024

PERIOD OF PERFORMANCE END DATE: 02/28/2029

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer